Side-by-side comparison
Biogen vs Johnson & Johnson
As of Sep 25, 2026, P/E is 24.5x for Biogen vs 31.5x for Johnson & Johnson; P/S is 3.4x for Biogen vs 6.7x for Johnson & Johnson; revenue growth is 1.2% for Biogen vs 8.1% for Johnson & Johnson; operating margin is 24.9% for Biogen vs 22.2% for Johnson & Johnson.
Key metrics
| Metric | BIIB | JNJ |
|---|---|---|
| Price | $227.60 | $271.22 |
| Market cap | $33.6B | $653.61B |
| P/E | 24.5x (#1) | 31.5x (#2) |
| P/S | 3.4x (#1) | 6.7x (#2) |
| Revenue growth | 1.2% (#2) | 8.1% (#1) |
| Operating margin | 24.9% (#1) | 22.2% (#2) |
| Net margin | 13.8% (#2) | 21.5% (#1) |
| Debt / equity | 0.34 (#1) | 0.44 (#2) |
| 1-year return | +65.7% (#1) | +50.9% (#2) |
| Research score | 67/100 (#1) | 65/100 (#2) |
Higher is better for growth, margins, one-year return and overall score; lower is better for valuation and debt ratios. Ties share a rank and missing values are excluded.
Company research
- Biogen Inc. (BIIB) — Drug Manufacturers—General
- Johnson & Johnson (JNJ) — Drug Manufacturers—General